Novo Nordisk Launches Ozempic in India for Type 2 Diabetes; Price Aligned with Wegovy

• Novo Nordisk has launched Ozempic, an injectable semaglutide, in India for Type 2 diabetes.
• Ozempic is available in 0.25, 0.5, and 1 mg strengths for diabetes, distinct from the 2.4 mg strength used for obesity.
• The pricing of Ozempic will be aligned with Wegovy's range, following a recent price cut for Wegovy.
• Novo Nordisk is engaged in legal disputes over semaglutide patents with Sun Pharma and Dr Reddy's.
• The company partnered with Mankind Pharma's M-Cure for a second Wegovy brand, Povidstra, to be launched soon.

Why It Matters: Ozempic's India launch offers new, potentially affordable, diabetes treatment for many.